Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Stay chill...certainly, but...
View:
Post by fox7mf on Feb 10, 2023 8:08pm

Stay chill...certainly, but...

It's my belief we'll get partnership/buyout news in March at some point. The 90-day right of first refusal, I believe, will have ended, and PFE will make their move. Sure, they want access to the most mature data available, but we have to remember that they & Merck have had real-time access to Bracelet data for the entire trial. I'm on record in my belief that Roche & Goblet have contributed to the wait. Onc stated that the winning bid would have to buy or license the entire package, so PFE all of a sudden would have to shell out for Pela/pancreatic as well as Pela/mBC & wtv else. So, doing the DD on both mBC & pancreatic, while doubling ones bid, is going to take time and create headaches, but will get done. Pela potentially provides quite a few revenue streams, so it's a valuable headache;)
Comment by Lesalpes29 on Feb 11, 2023 8:38am
If something is to unfold on the buyout side it will happen before june. I don't think BP want to slow the process for many reasons. I think BP know enough actually to be in negociation since before december (just after onc added the 2 new directors) and what will speed the process it's the interest of more than one BP. And let imagine a P3 announce in the coming weeks! A first offer will ...more  
Comment by fox7mf on Feb 11, 2023 9:42am
Yeah, I believe the Car-t summit in Feb, which Oncy' is a presenter at, won't even illicit an NR from the company. NDA'S. Parsons was actually appointed way back in June, and Rigby in September, so Onc and their BP partners have known for a long time that the negotiations would be very involved & intense. Something will come to a head soon.
Comment by Buckhenry on Feb 11, 2023 10:18am
my prediction is............ if there is buyout news we will here about it through the proper channels at the proper time.  
Comment by Hydroqc on Feb 11, 2023 10:29am
Finally, you say something that make sens Buck.
Comment by Buckhenry on Feb 11, 2023 11:43am
thanks much.... I just wished others here would follow suit instead of texting jibrish. 
Comment by Azzak34 on Feb 11, 2023 3:43pm
Don't get carried away idiot, it's your first and likely last bit of sense. 
Comment by Buckhenry on Feb 12, 2023 10:28pm
you sound so lost and bitter azzak... u hope you get some professional help
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities